生物帮生物通

采购帮忙热线
020-87540820
020-38498013
 
当前位置: 首页 » 行业资讯 » 行业资讯 » 正文

产前诊断技术公司Ariosa Diagnostics IPO拟融资6900万美元

放大字体  缩小字体 发布日期:2014-03-28  来源:来宝网  浏览次数:108

美国Ariosa Diagnostics
 
2014年3月25日 美国生物科技创业公司Ariosa Diagnostics(以下简称“Ariosa”)本周二已向美国证券交易委员会(SEC)提交了首次公开招股(IPO)申请文件,称计划通过此次IPO最高融资6900万美元。

Ariosa创建于2008年,其旗舰产品“Harmony产前检测”是一项确保孕产妇和胎儿

 

健康的产前检测技术。它通过血液检测方式,确定胎儿是否患有唐氏综合症及其他染色体疾病。去年Ariosa营收额为5300万美元。Ariosa计划在纳斯达克上市,股票交易代码为“AROS”,摩根大通(JPMorgan Chase)和花旗集团为联合承销商。在提交给SEC的S-1管理文件中,Ariosa没有公布此次IPO的发行价区间。

目前孕妇产前检测市场的竞争程度非常激烈。去年,Ariosa在产前检测专利战予以主要竞争对手Sequenom重创。Ariosa称,将把此次IPO所获资金主要用于Harmony市场推广以及公司今后的收购活动。自2012年起,Ariosa已开始在美国和加拿大市场推广其Harmony产品。

Ariosa在S-1管理文件中还透露,目前Harmony产品已在全球90多个国家和地区销售,今后将进一步扩大产品的市场范围以及所面向的孕妇人群。

 

NIPT Firm Ariosa Diagnostics Files for IPO

Ariosa Diagnostics has filed a regulatory document with the US Securities and Exchange Commission for an initial public offering.

In its preliminary prospectus filed with the SEC on Monday, the San Jose, Calif.-based developer of non-invasive prenatal tests said it intends to offer $69 million in a proposed maximum aggregate offering price. It has not priced its shares yet or said how many share it plans to offer.

Ariosa said that it plans to list its shares on the Nasdaq Global Market under ticker symbol "AROS."

JP Morgan and Citigroup Global Markets are acting as joint book-running managers on the planned IPO. William Blair and Leerink Swann are also named as underwriters.

Formed in 2008 as Tandem Technologies, the company changed its name to Aria Diagnostics before changing it again to Ariosa in 2012. Its lead product is the Harmony Prenatal Test, launched in early 2012 and performed out of Ariosa's CLIA-certified laboratory. The company has a non-exclusive agreement with the Laboratory Corporation of America to offer Harmony in the US and Canada.

Ariosa operates in one of the fastest growing markets in the next-generation sequencing space, and according to a recent report from market research firm DeciBio, the majority of the $100 million worldwide NGS molecular diagnostic market in 2012 consisted of non-invasive prenatal testing. By 2015, the report said, the NIPT market will grow to around $600 million, or ab0ut half of the estimated total NGS molecular diagnostic market, as Clinical Sequencing News reported.

Ariosa's competitors in the NIPT space include Sequenom, Natera, and Illumina's Verinata Health. Quest Diagnostics, Berry Genomics, BGI, and LifeCodexx also offer NIPTs.

In addition to being highly competitive, the NIPT space has been highly litigious. In 2011, Ariosa sued Sequenom saying it was overly aggressive in its enforcement of a broad patent related to the use of circulating cell-free DNA in maternal plasma to diagnose fetal aneuploidies. In early 2012 Sequenom returned volley and sued Ariosa, alleging patent infringement. Later that year, Verinata and Stanford Universityalso took Ariosa to court accusing it of patent infringement.

Ariosa's filing for an IPO follows a federal court's ruling in late October that invalidated US Patent No. 6,258,540, which underlies Sequenom's MaterniT21 Plus NIPT, a ruling that was viewed as a victory, at least temporarily, for Sequenom's competitors.

Sequenom has appealed the decision to the United States Court of Appeals for the Federal Circuit. At the time of the ruling, though, Ariosa called it a "complete victory" that "validates the company's long-standing view that it has freedom to develop new, innovative, and market-leading technologies to provide improved genetic testing for pregnant women."

Ariosa's Harmony is a blood-based test that eva1uates cell-free DNA from the fetus found in maternal circulation to asses the risk of fetal aneuploidies, including trisomy 21,18, and 13. Since Harmony's launch, Ariosa has tested more than 185,000 pregnant women through the end of 2013, including more than 45,000 in the Q4 2013, it said in its Form S-1.

In its SEC document, Ariosa said that it believes Harmony "represents the next generation of NIPT, as it was developed to be a first-line test for the general pregnancy population," as opposed to the high-risk pregnancy population that some of its competitors target with their tests.

"By combining proprietary methods for targeted sequence analysis, bioinformatics analysis and an automated high-throughput laboratory process, we are able to provide highly accurate results at affordable prices," the company said. "Compared to traditional first-line screening options, such as serum protein measurement, Harmony can be used any time after 10 weeks into pregnancy with higher detection and lower false positive rates for Down syndrome and can provide information on fetal sex."

Harmony is available in more than 90 countries, and in 2012, Ariosa recorded revenues of $12 million and a net loss of $21.9 million. In 2013, revenues increased to $53.3 million, while net loss shrank to $2.4 million.

It had $14.1 million in cash and cash equivalents and 140 employees as of the end of 2013.

Key members of its management team include CEO Kenneth Song; President and COO David Mullarkey; CFO Daniel Puckett; Chief Medical Officer Thomas Musci; and Chief Scientific Officer Arnold Oliphant.

 
 
[ 行业资讯搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

0条 [查看全部]  相关评论

 
推荐行业资讯
点击排行
 
网站首页 | 企业资料认证流程 | 广告服务 | 关于我们 | 联系方式 | 使用协议 | 网站地图 | 排名推广 | 广告服务 | 网站留言 | RSS订阅 | 粤ICP备11050685号-8